Olaparib effective in four advanced cancers.

Cancer discovery ·第 5 卷 ·第 1 期 ·2015-09-10

摘要

In a phase II study, researchers found that the PARP inhibitor olaparib led to stable disease or tumor regressions in patients with advanced breast, ovarian, pancreatic, and prostate cancers who had germline mutations in BRCA1 or BRCA2.

文献信息

期刊

Cancer discovery

期刊简称

Cancer Discov

ISSN

2159-8274

DOI

10.1158/2159-8290.CD-NB2014-176

发表日期

2015-09-10

收录日期

2015-01-13

更新日期

2015-11-19

语言

英语

国家/地区

United States

NLM ID

101561693

外部链接

PubMed 原文 DOI: 10.1158/2159-8290.CD-NB2014-176 查看期刊详情

分析服务

Olaparib effective in four advanced cancers.

联系地址

微信公众号